Automatic Data Processing, Inc. R&D decreased by 1.5% to $253.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.8%, from $247.10M to $253.90M. Over 3 years (FY 2022 to FY 2025), R&D shows an upward trend with a 7.4% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $199.65M | $199.65M | $199.65M | $199.65M | $209.80M | $204.20M | $208.60M | $222.20M | $236.50M | $228.70M | $242.70M | $247.90M | $232.60M | $239.50M | $247.10M | $269.40M | $251.20M | $257.80M | $253.90M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +5.1% | -2.7% | +2.2% | +6.5% | +6.4% | -3.3% | +6.1% | +2.1% | -6.2% | +3.0% | +3.2% | +9.0% | -6.8% | +2.6% | -1.5% |
| YoY Change | — | — | — | — | +5.1% | +2.3% | +4.5% | +11.3% | +12.7% | +12.0% | +16.3% | +11.6% | -1.6% | +4.7% | +1.8% | +8.7% | +8.0% | +7.6% | +2.8% |